# A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer

> **NCT02831491** · PHASE2 · WITHDRAWN · sponsor: **Eli Lilly and Company**

## Conditions studied

- Stage IV Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Ramucirumab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT02831491
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-11
- **Primary completion:** 2017-07
- **Final completion:** 2018-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** To pursue broader program objectives in oncology.
- **Last updated:** 2020-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02831491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02831491, "A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02831491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*